LATEST ONCOPRESCRIBE UPDATES
Neoadjuvant KEYTRUDA® plus Chemotherapy Significantly Improves EFS in Early Stage High Risk Triple Negative Breast Cancer
Metformin May Reduce the Risk of Cancers, Especially GI Malignancies
FDA Approves BREYANZI®, First CAR-T Cell Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
FDA Approves TEVIMBRA® for Advanced Esophageal Squamous Cell Carcinoma
FDA Approves RYBREVANT® in Combination with Chemotherapy for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approves OPDIVO® in Combination with Chemotherapy for the First Line Treatment of Advanced Urothelial Carcinoma
Stockholm3 Blood Test Identifies Aggressive Prostate Cancer
FDA Approves ONIVYDE® for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma